Clinical DataRP1 + Opdivo achieved an objective response rate of 33.6% in anti-PD1 failed melanoma patients, which is significantly higher than what would be expected with an anti-PD1 agent alone.
Commercial StrategyThe company has completed the buildout of its commercial infrastructure, including customer-facing teams and distribution channels, in anticipation of RP1's potential market launch.
Regulatory ApprovalThe FDA interactions remain positive and the company is confident in timely approval despite FDA changes.